Transgene Announces Achievement of Clinical Milestone by Merck & Co., Inc. Using Transgene's Proprietary Technology
Transgene granted Merck a non-exclusive license for this technology in January 2003 and expects to receive, in addition to the initial license fee and annual maintenance fees, milestone payments based on the further development of products by Merck, as well as royalties on any marketed products.
"The initiation of a Phase I trial triggers the first clinical milestone payment under the license agreement signed between Merck and Transgene," said Philippe Archinard, Chief Executive Officer of Transgene. "We are pleased that Merck is making further progress towards developing vaccines using our proprietary technology."
Transgene, based in Strasbourg, France is a biopharmaceutical company dedicated to the discovery and development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. Transgene has a broadportfolio of clinical stage immunotherapy drugs, technologies available for out-licensing and viral vectors bio-manufacturing capacities.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.